Chinese traditional medicine has been listed in the United States Pharmacopoeia and dozens of drugs are under review

On August 7, the National Health and Family Planning Commission held a press conference. Zhang Boli, president of the China Academy of Chinese Medical Sciences, said that China's traditional Chinese medicine standards have been included in the United States Pharmacopoeia, and dozens of drugs are now being reviewed by the United States Pharmacopoeia Committee, and it is estimated that they will be included in the United States Pharmacopoeia in recent years.

Zhang Boli pointed out that China’s major special projects also pay great attention to the research and development of new traditional Chinese medicines and the internationalization of traditional Chinese medicines, and have also deployed topics in this area. In particular, it supports the registration research of new traditional Chinese medicines in European and American countries, that is, the clinical evaluation of traditional Chinese medicines in accordance with the standards of European and American countries. In this area, nearly 7 drugs are currently undergoing clinical research in the United States. Among them, three drugs, Compound Danshen Dropping Pills, Xuezhikang, and Fuzheng Huayu Capsules, have completed Phase II clinical studies, some have already launched Phase III clinical studies, and some are preparing to launch Phase III clinical studies.

Guizhi Fuling Capsules are undergoing phase II clinical research, and the progress is relatively smooth. At the same time, registration studies have also been carried out in the EU. Among them, Di'ao Xinxuekang has completed the registration work, and several other drugs are in progress. It is expected that they will also be successfully registered in the next one or two years. This batch of drugs was registered in European and American countries, increasing the influence of traditional Chinese medicine.

Zhang Boli emphasized that there are some Chinese standards for traditional Chinese medicine, such as Salvia miltiorrhiza, which has been included in the United States Pharmacopeia. This is the first Chinese medicine in our country to be included in the United States Pharmacopeia. There are still dozens of drugs under review by the United States Pharmacopoeia Committee, and it is estimated that they will be included in the United States Pharmacopeia in the next few years. This is also a very significant progress. The standards of Chinese medicinal materials have been incorporated into the United States Pharmacopoeia, and they will also require botanical medicines according to this standard, which provides a basis for more of our medicines to enter the United States. In general, major special projects have played a positive role in promoting the modernization of traditional Chinese medicine and the internationalization of traditional Chinese medicine, and have also made certain progress.